Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025

Trial Profile

A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KD 025 (Primary) ; Itraconazole; Rabeprazole; Rifampicin
  • Indications Autoimmune disorders; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis; Systemic scleroderma
  • Focus Pharmacokinetics
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 12 Aug 2019 Status changed from recruiting to completed.
    • 11 Oct 2018 Number of treatment arms has been increased hence number of patients has also increased. Endpoints has also added.
    • 11 Oct 2018 Planned number of patients changed from 40 to 78.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top